Lilly acquires Ventyx Biosciences

Lilly agreed to acquire Ventyx Biosciences. Reported deal value: $1B. Status: Announced. Sector: Pharmaceuticals. Target headquarters context: San Diego, California, United States.

This page summarizes publicly available information about the transaction as of 2026-01-07. Figures and status may change as filings and press coverage update.

Eli Lilly and Company and Ventyx Biosciences , Inc. , a San Diego -based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory - mediated diseases , today announced entry into a definitive agreement for Lilly to acquire Ventyx . Ventyx is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation across a broad range of disease states with high unmet need